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Abstract  
Successful pathogens use complex signaling mechanisms to monitor their environment and 
reprogram global gene expression during specific stages of infection. Group A Streptococcus 
(GAS) is a major human pathogen that causes significant disease burden worldwide. A secreted 
cysteine protease known as streptococcal pyrogenic exotoxin B (SpeB) is a key virulence factor 
that is produced abundantly during infection and is critical for GAS pathogenesis. Although 
identified nearly a century ago, the molecular basis for growth phase control of speB gene 
expression remains unknown. We have discovered that GAS uses a previously unknown peptide -
mediated intercellular signaling system to control SpeB production, alter global gene expression, 
and enhance virulence. GAS produces an eight amino acid leaderless peptide [SpeB-inducing 
peptide (SIP)] during high cell density and uses the secreted peptide for cell-to-cell signaling to 
induce population-wide speB expression. The SIP signaling pathway includes peptide secretion, 
reimportation into the cytosol, and interaction with the intracellular global gene regulator regulator 
of Protease B (RopB), resulting in SIP-dependent modulation of DNA binding and regulatory 
activity of RopB. Notably, SIP signaling causes differential expression of ∼14% of GAS core 
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genes. Several genes that encode toxins and other virulence genes that enhance pathogen 
dissemination and infection are significantly up-regulated. Using three mouse infection models, 
we show that the SIP signaling pathway is active during infection and contributes significantly to 
GAS pathogenesis at multiple host anatomic sites. Together, our results delineate the molecular 
mechanisms involved in a previously undescribed virulence regulatory pathway of an important 
human pathogen and suggest new therapeutic strategies. 
 
Publication 2 
Makthal N, Do H, VanderWal AR, Olsen RJ, Musser JM, Kumaraswami M. Signaling by a 
Conserved Quorum Sensing Pathway Contributes to Growth Ex Vivo and Oropharyngeal 
Colonization of Human Pathogen Group A Streptococcus. Infection and Immunity 86:e00169-18. 
Abstract 
Bacterial virulence factor production is a highly coordinated process. The temporal pattern of 
bacterial gene expression varies in different host anatomic sites to overcome niche-specific 
challenges. The human pathogen group A streptococcus (GAS) produces a potent secreted 
protease, SpeB, that is crucial for pathogenesis. Recently, we discovered that a quorum sensing 
pathway comprised of a leaderless short peptide, SpeB-inducing peptide (SIP), and a cytosolic 
global regulator, RopB, controls speB expression in concert with bacterial population density. The 
SIP signaling pathway is active in vivo and contributes significantly to GAS invasive infections. 
In the current study, we investigated the role of the SIP signaling pathway in GAS-host interactions 
during oropharyngeal colonization. The SIP signaling pathway is functional during growth ex vivo 
in human saliva. SIP-mediated speB expression plays a crucial role in GAS colonization of the 
mouse oropharynx. GAS employs a distinct pattern of SpeB production during growth ex vivo in 
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saliva that includes a transient burst of speB expression during early stages of growth coupled with 
sustained levels of secreted SpeB protein. SpeB production aids GAS survival by degrading LL37, 
an abundant human antimicrobial peptide. We found that SIP signaling occurs during growth in 
human blood ex vivo. Moreover, the SIP signaling pathway is critical for GAS survival in blood. 
SIP-dependent speB regulation is functional in strains of diverse emm types, indicating that SIP 
signaling is a conserved virulence regulatory mechanism. Our discoveries have implications for 
future translational studies. 
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ABSTRACT 
Quorum sensing (QS) is a process in which bacteria use diverse signaling molecules to 
monitor their population density and regulate population-wide expression of genes involved in 
several key bacterial processes such as virulence, biofilm formation, and antibiotic resistance. 
Gram-positive bacteria typically use oligopeptides as intercellular signaling molecules. The 
secreted oligopeptides modulate gene expression by either activating the sensor kinase of a two-
component system on the bacterial surface or by interacting with cognate transcription regulator 
in the bacterial cytosol. The gram-positive bacteria Group A Streptococcus (GAS) is a major 
human pathogen responsible for over 700 million infections annually worldwide. GAS produces a 
wide spectrum of virulence factors that play crucial roles in disease pathogenesis. Among the many 
toxins produced by GAS, Streptococcal pyrogenic exotoxin B (SpeB) is one of the well-studied 
virulence factor. SpeB is a secreted cysteine protease that is produced abundantly during infection 
and is critical for GAS pathogenesis. Although SpeB is extensively studied for a century, the 
precise regulatory events that govern speB gene expression are not fully understood. In this study, 
we have discovered that GAS employs a previously unknown peptide-mediated quorum sensing 
pathway to control speB expression during high bacterial population density. GAS genome 
encodes a novel class of leaderless peptide signal, SpeB-Inducing Peptide (SIP). SIP lacks several 
characteristic features that are hallmarks of bacterial peptide signals. Contrary to all the 
characterized bacterial peptide signals, SIP is produced in its mature form and lacks amino acid 
sequences in the amino terminus required for secretion. Nevertheless, SIP functions as an effective 
intercellular signal. SIP is secreted and reinternalized into GAS cytosol where it interacts with its 
cognate regulator, Regulator of proteinase B (RopB). SIP binding to RopB induces allosteric 
changes in the regulator, which leads to high affinity RopB-DNA interactions, RopB 
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oligomerization and activation of speB gene expression. Importantly, we demonstrate that the SIP 
signaling pathway is active in vivo and contributes significantly to GAS virulence in multiple 
mouse models of GAS infection. We also show that the SIP signaling occurs during GAS growth 
ex vivo in human saliva and blood and SIP-mediated speB expression is crucial for GAS survival 
in both saliva and blood. Together, our discoveries in this study identify a novel bacterial signaling 
pathway and suggest new therapeutic strategies for future translation studies.    
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INTRODUCTION 
The discovery of antibiotics and the ability to treat bacterial infections have revolutionized 
human health care in many respects (5). Since the discovery of penicillin in 1928, several natural 
or synthetic antimicrobial agents have been developed (6). However, abuse and overuse of 
antibiotics in the subsequent decades have endangered the efficacy of antibiotics due to the rapid 
emergence of drug-resistant bacteria (7-9). New drugs are being developed by the pharmaceutical 
industry to overcome bacterial antimicrobial resistance. However, the pipeline began to dry out in 
the recent years, posing an imminent threat to human health care (6, 10). Thus, novel approaches 
are needed to identify and characterize new antimicrobials to prevent/treat drug-resistant bacterial 
infections. In this regard, a complete understanding of bacterial virulence mechanisms is crucial 
in our efforts to devise targeting strategies and develop future antimicrobials (5).   
 
1.1 Group A Streptococcus and its pathogenesis  
Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a gram-positive, 
non-spore forming, cocci bacterium (11). GAS is an exclusive human pathogen that causes a vast 
spectrum of pyogenic disease conditions in oropharyngeal (throat) and skin mucosal surfaces, 
resulting in pharyngitis (commonly known as “strep throat”) and impetigo respectively (Fig. 1) (2, 
12-16). Pharyngitis is the most common GAS disease manifestation with over 600 million cases 
worldwide, affecting approximately 20 – 40% of children and 10 – 15% of adults every year (17, 
18). GAS persists in human saliva by overcoming the host innate and acquired immune system. 
The survival of GAS in saliva is crucial for person-to-person disease transmission, presumably via 
saliva droplets (18-20). Impetigo is a highly contagious skin disease spread through direct skin 
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contact resulting in approximately 111 million global cases every year, mostly in children from 
developing countries (19, 21).  
Recurring untreated pharyngitis can lead to post-infection auto immune disorders such as 
acute rheumatic fever (ARF), rheumatic heart disease (RHD), and acute post-streptococcal 
 
Figure 1. Overview of diseases caused by GAS infections. Common disease manifestations caused by 
GAS infections in human. Adapted from (1).     
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glomerulonephritis (APSGN) (Fig. 1) (19, 22, 23). ARF and RHD constitute the major cause of 
morbidity and mortality caused by GAS infections. Globally, approximately 2.4 million children 
develop heart disease as a result of RHD every year (15, 24). Consequently, RHD is the most 
preventable pediatric heart disease in the world (25, 26). APSGN is an autoimmune disorder of 
kidneys, sequelae of GAS pharyngitis or impetigo. The most common clinical features include 
edema, hypertension, proteinuria, urinary sediment abnormalities (19, 27). Half a million cases are 
recorded every year worldwide that results in approximately 1% mortality (13).  
In complicated cases, GAS invades epithelial barriers and penetrates into deeper tissues, 
which can lead to severe life-threatening invasive infections (11, 28). Bacteremia and cellulitis are 
the most common GAS invasive diseases. GAS infections can also lead to less common, but 
difficult to treat invasive diseases such as necrotizing fasciitis (also known as “flesh-eating 
disease”), and streptococcal toxic shock syndrome (STSS) (also known as “bacterial sepsis”) (15, 
19, 29-31). Invasive infections are responsible for approximately 500,000 deaths every year 
worldwide (19, 32). Due to the global disease and economic burden caused by GAS infections, 
GAS is listed as one of the top ten infectious causes of mortality (19, 33). 
 Though mild GAS infections can be treated with penicillin and cephalosporin, recent 
studies have reported a 20 – 40% failure rate of penicillin in treating pharyngitis (34, 35). 
Moreover, GAS resistance to other antibiotics in developing countries is on the rise and is a 
worldwide concern (19). Contrary to mild infections, invasive infections are unresponsive to 
antibiotics treatment and often require surgical intervention for infection control. Similarly, RHD 
disease control requires expensive long-term antibiotics administration, and/or surgical 
debridement of infected valves (15, 19). Thus, a human GAS vaccine will be highly beneficial in 
GAS disease prevention. A great deal of work has been done in the last 70 years on M protein 
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(encoded by emm gene) as a potential candidate for the development of a vaccine. However, the 
existence of more than 200 emm type variations in GAS and the associated antigenic diversity pose 
a major roadblock for the development of single effective universal M protein based GAS vaccine 
(20). Furthermore, the antibodies developed against M protein cross-react with human heart tissue 
and trigger the development of ARF and RHD. Thus, the need for the identification of novel 
vaccine or antimicrobial targets to treat or prevent GAS diseases is urgent (36-38). As a result, 
continued investigations into basic virulence pathways is imperative to elucidate novel therapeutic 
and/or prophylactic strategies toward GAS infection control.  
 
 
2. Virulence factors  
The ability of GAS to successfully colonize, evade the immune system and invade different 
host niches depends on the spatiotemporal production of wide array of virulence factors (Fig. 2) 
(37). GAS virulence factors are categorized into two groups depending on their location; cell 
surface-associated and secreted toxins (2, 16, 37). 
 
2.1 Cell-associated virulence factors  
GAS genome encodes multiple adhesins such as collagen binding proteins, fibronectin (Fn) 
binding proteins (Sfb1, SfbII, SOF, PrtF2, FbpA, FbaB and Pfbp), lipoteichic acids (LTA), and 
plasminogen binding proteins that play a crucial role in host cell attachment (Fig. 2) (37, 39, 40). 
Virulence factors such as the immunoglobulin binding proteins (M protein superfamily, SibA), 
C5a peptidase, hyaluronic acid capsule, lipoprotein (Lsp), streptococcal protective antigen (Spa), 
heme-binding protein, HtrA protease, streptococcal collagen-like surface proteins (Scl1 and Scl2), 
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CD15s-related antigen, plasminogen binding proteins and serum opacity factor cleave host 
immune factors and aid GAS in immune evasion (Fig. 2) (37). Amongst the many cell-associated 
virulence factors, M protein and hyaluronic acid capsule (produced by hasABC gene cluster) are 
the two best-studied factors (15, 37). M protein confers phagocytosis resistance by binding to host 
immune effectors such as complement-inhibitory proteins C4BP, factor H, and factor H-like 
protein (41-43). Similarly, hyaluronic acid capsule also provides antiphagocytic function by 
restricting the access of GAS surface to opsonins (44, 45).  
Figure 2. Virulence factors encoded in GAS genome. GAS produces several virulence factors that 
contributes to disease pathogenesis by facilitating host cell attachment, anti-phagocytosis, immune invasion, 
and immune evasion. Cell-associated factors are shown on the surface of GAS and secreted factors are 
indicated by black arrows. Blue boxes show the list of virulence factors. Orange boxes show the list of 
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2.2 Extracellular secreted virulence factors  
 GAS produces several major secreted virulence factors such as hemolysins, DNAses, 
superantigens (SAgs), and proteases (Fig. 2) (46). Streptolysin O (SLO) is a major pore-forming 
hemolysin that disrupts the integrity of host cell membrane and induces apoptosis (47). 
Streptolysin S (SLS), a second hemolysin encoded by GAS, contributes to GAS virulence in 
several ways that include host cell cytotoxicity, activation of inflammatory responses, and 
antiphagocytosis (46, 48). The host innate immune system deploys neutrophil extracellular traps 
(NETs) to control bacterial growth. NETs contain bactericidal proteases on webs of DNA (49). To 
counter this, GAS produces several secreted DNAses, such as streptodornase (Sdn), and 
streptodornase- (Sda). GAS-encoded DNAses degrade NETs by digesting DNA and aid immune 
evasion (46, 49). Streptococcal inhibitor of complement (SIC) contributes to GAS pathogenesis 
by degrading several host cells, including lymphocyctes and erythrocyctes (50). SIC can also 
disrupt the host signals involved in producing antimicrobial peptides (AMPs) and facilitate GAS 
survival in the host (51, 52). GAS superantigen proteins such as SPE A, SPE C, SPE G-M, 
streptococcal mitogenic exotoxin Z (SmeZ) and streptococcal superantigen A (SSA) belong to a 
family of highly mitogenic exotoxins (53, 54). SAgs share the ability to trigger overstimulation of 
T lymphocytes, which leads to the release of pro-inflammatory cytokines and development of 
STSS (53). GAS secretes many proteases such as SpeB, PrtS, IdeS, and SpyCEP that contribute 
significantly to GAS pathogenesis by facilitating host tissue degradation and disease dissemination 
(46). In addition, GAS produces secreted esterases such as SsE, CAMP factor, hyaluronidases such 
as HlyP, HlyA, and soluble M proteins that contributes significantly towards the success of GAS 
pathogenesis (46). 
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3. Major virulence factor - Streptococcal pyrogenic exotoxin B 
Among the several virulence factors produced by GAS, SpeB is a major secreted toxin that 
plays a critical role in GAS disease pathogenesis (55). Streptococcal pyrogenic exotoxin B (SpeB), 
also known as streptopain, is one of the most extensively studied GAS virulence factors (2, 14). 
SpeB is the predominant extracellular virulence factor in GAS culture supernatant during growth 
in vitro (56). Although the established name for this enzyme is SpeB, SPE B is still occasionally 
used in the literature (2, 14). Two separate branches of investigation independently identified the 
same molecule but classified it differently (2). Nearly a century ago, a secreted protease activity 
was observed in streptococcal growth (57). Subsequent biochemical studies demonstrated that the 
protease activity in the secreted component of streptococcal growth was similar to cysteine 
protease papain and classified it as a cysteine protease (2, 14, 58). In a parallel line of investigation, 
exotoxins were identified in the streptococci culture filtrates obtained from patients with scarlet 
fever and were designated as superantigens SPE A, SPE B, and SPE C (53, 59). Significant 
technological advances in the molecular techniques later revealed that the observed superantigen 
activity of SPE B was likely the result of other streptococcal contaminants (60). In subsequent 
years, detailed genetic analysis revealed that SPE B and cysteine protease are the same protein 
encoded by the GAS genome. Importantly, it was concluded that SpeB is not a superantigen, it is 
rather a cysteine protease (61). Although SpeB is neither pyrogenic nor exotoxin, the designation 
is widely employed by researchers over the years and retained in the current literature. 
 
3.1 Role of SpeB in GAS pathogenesis  
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Several lines of study have provided evidence that SpeB is a critical player in GAS 
pathogenesis (62-66). The chromosomally encoded speB gene is highly conserved in virtually all 
disease-causing GAS isolates (67-69). Inactivation of SpeB attenuated GAS virulence in multiple 
mouse models and non-human primate model of GAS infection (70-75). SpeB is crucial for GAS 
survival and proliferation ex vivo in human saliva and blood (76-81), suggesting that the protease 
activity of SpeB is critical for GAS virulence. SpeB contributes to GAS pathogenesis in two major 
ways, immune evasion by degrading immune molecules and disease dissemination by proteolytic 
degradation of host tissue matrix proteins and GAS surface proteins (Fig. 3) (14).   
The substrate profile of SpeB includes a myriad of host and bacterial proteins. 
Immunoglobulins (Ig), secreted by B cells of the host adaptive immune system plays a critical role 
in neutralizing pathogens. SpeB aids GAS immune evasion by degrading multiple classes of 
immunoglobulins including IgA, IgM, IgD, and IgE (82). SpeB-mediated cleavage of IgG results 
in decreased opsonophagocytosis (14, 83). In addition to Ig, SpeB also cleaves several host 
immune effectors such as complement component C3b (84), signals required for the activation of 
antimicrobial cytokines (14, 85), host interleukin I β (IL-1β) (63), and kininogen (86), resulting in 
induction of inflammatory responses. SpeB can degrade the antimicrobial peptide (AMP) LL-37 
directly (87) or indirectly by promoting the release of dermatan sulfate from decorin (88). The 
proteolytic activity of SpeB contributes indirectly to GAS immune evasion by releasing several 
GAS surface associated virulence factors (14, 89, 90). SpeB releases the mature form of M protein 
from GAS surface to confer resistance to phagocytosis (90, 91). SpeB-dependent cleavage of 
protein H aids GAS immune evasion by the binding of protein H fragment to host IgG and 
inhibition of host complement activation (92). C5a peptidase is an important virulence factor 
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anchored to GAS surface and C5a released by SpeB-mediated cleavage inhibits chemotactic 
recruitment of phagocytic cells to the site of infection (90, 93). 
The proteolytic activity of SpeB contributes to GAS dissemination into deeper host tissues  
by enzymatic degradation of host tissue (72, 74, 75, 94-96). SpeB cleaves major host tissue matrix 
proteins fibronectin and degrades vitronectin and contributes to tissue destruction (97). The 
Figure 3. SpeB biogenesis and its contribution to GAS pathogenesis. SpeB is produced and secreted in 
an inactive zymogen precursor form (SpeBZ). Auto-cleavage of SpeBZ results in the release of mature active 
cysteine protease (SpeBM). The title of individual gray boxes represents the SpeBM activity on host factors. 
Left column in each grey box indicates the identity of SpeBM substrate, whereas the right column represents 
the consequences of SpeBM activity on those factors. Adapted from (2) 
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protease activity of SpeB has been implicated in the induction of caspase-dependent apoptosis in 
host epithelial cells (98). 
GAS produces SpeB during human infection (99, 100). Infected humans produce anti-SpeB 
antibodies (101, 102) and low antibody titers correlate with severe invasive disease (102, 103), 
suggesting that SpeB participates in GAS pathogenesis during natural infection. Consistent with 
this, immunization of mice with SpeB reduced mortality caused by experimental GAS infections 
(104-107). Similarly, mice treated with a small molecule protease inhibitor conferred protection 
against GAS invasive diseases (62), suggesting that SpeB is an ideal therapeutic or prophylactic 
target to treat GAS infections. Collectively, these observations indicate that SpeB is a major GAS 
virulence factor that contribute to GAS pathogenesis in the host.  
 
3.2 Biogenesis of SpeB protease  
The full-length SpeB is a 398 amino acid long protein with a molecular mass of 43 kilo 
daltons (kDa) (Fig. 4). The first 27 amino acids in the amino terminus of SpeB harbor the secretion 
signal sequence that facilitates its transport out of the cytosol. SpeB is initially made in an inactive 
form, known as zymogen (SpeBZ) (amino acids 28 – 398) (Fig. 3 and 4). The pro-domain (amino 
acids 28 – 145) is inserted into the active site of SpeB in the zymogen form and keeps the protease 
Figure 4. Schematic diagram showing the domain architecture of SpeB. The individual domains and 
motifs in the full-length SpeB are marked and labeled as follows: grey box represents the secretion signal 
sequence; orange box indicates the pro-domain; and green box represent the mature cysteine protease 
(SpeBM). The structural elements color coded in orange and green boxes represent the inactive pre-cursor 
SpeB zymogen form. The numbers above indicate the amino acids that constitute each highlighted SpeB 
domain. Adapted from (2).    
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enzymatically inactive in GAS cytosol. Upon secretion to the extracellular environment, SpeBZ 
undergoes several autocatalytic steps, which results in the cleavage of pro-domain and release of 
the mature active cysteine protease (amino acids 146 – 398, SpeBM) (Fig. 3 and 4) (2). Genetic 
and structural studies identified the active site of the protease that is comprised of amino acids 
cysteine 192, histidine 340 and tryptophan 357. The catalytic site of SpeBM is essential for SpeB 
maturation and its proteolytic activity (2, 108, 109). In accordance with the role of SpeB as a major 
GAS virulence factor, the biogenesis of SpeB is a multistage process that is controlled by several 
GAS factors at transcriptional, post-transcriptional and translational levels (Fig. 5) (2, 68). 
Figure 5. Schematic diagram showing the factors involved in the regulation of SpeB. Boxes to the left 
represent the level of SpeB regulation. Corresponding color-coded boxes to the right show the factors 
involved and their known effect on the respective level of regulation.   
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3.3 Transcription regulation of speB 
GAS-encoded factors as well as environmental factors such as pH and NaCl were 
implicated in the regulation of speB expression (Fig. 5) (2, 89, 110-112). Although the 
environmental signals contribute to transcription regulation of speB, the molecular mechanisms of 
how pH and salt mediate transcription regulation of speB are yet to be elucidated. It is possible 
that specific pH and salt requirements for speB expression may mimic host niche environments 
GAS encounters during infection (110). Expression of speB is under the control of 13 different 
GAS-encoded transcription factors (Fig. 5) (2). The GAS global transcription regulator, the 
Regulator of proteinase B (RopB), is located in the genetic vicinity of speB gene and is essential 
for speB expression (2, 71, 113, 114). The ropB and speB genes are divergently transcribed and 
separated by a 940 nt intergenic region (Fig. 6) (71, 114). Expression of speB is driven from two 
individual transcription start sites (TSS), P and P1, located 842 nt and 697 nt upstream of the speB 
gene (115, 116). A third TSS, P2 located at 137 nt upstream of speB gene was previously 
identified, however, it was recently re-annotated as a RNase Y processing site of speB mRNA 
(Fig. 6) (114, 116). In addition to the complex transcription process (Fig. 5), the intergenic region 
also harbors several important regulatory factors and small open reading frames (orf) whose 
functions are yet to be elucidated (Fig. 6) (2, 114-116). 
 SpeB production is growth phase-dependent and speB expression predominantly occurs 
during stationary phase of GAS growth or high GAS population density (110, 117). Similar to 
speB, maximum expression of ropB also occurs during late exponential phase (114).  Transcription 
of speB is under the direct control of RopB. The speB promoter has binding sites for RopB and the 
occupancy of RopB at speB promoter is critical for the upregulation of speB expression (2, 114). 
Although RopB is essential for the activation of speB transcription, ectopic expression of ropB 
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from a constitutive promoter during early exponential phase of growth or low population density 
was not sufficient to activate speB expression (2, 114). This observations suggest that additional 
high population density-specific regulatory factors are required to activate RopB-dependent speB 
expression. Consistent with this, the addition of cell-free culture supernatant obtained from high 
GAS population density to cells grown to low bacterial population density induced speB 
expression, suggesting the presence of unidentified high population density-specific secreted 
activation factor(s) (71). 
  
4. Quorum-sensing in bacteria 
Bacteria communicate with each other by a process called quorum sensing (118, 119). It 
involves the production and secretion of small molecules known as autoinducers (AIs), and sensing 
of the AIs by cognate receptors in the neighboring cells (118-120). At low bacterial population 
density, the concentration of AIs is below the threshold concentration required to elicit responses 
in the neighboring cells. However, at high bacterial population density, AIs reach critical threshold 
concentration and evoke transcriptional responses in a population-wide fashion (118, 120-122). 
Figure 6. Schematic diagram showing the genetic organization of ropB and speB genes. Promoter 
region of speB (PspeB) and ropB (PropB) are marked by bent arrows above and below the line, respectively. 
The coding regions of ropB, speB and predicted open reading frames, orf-2 and orf-3, are shown as block 
arrows. The start codon of SpeB coding region is marked as +1 and the number below the line indicate the 
location of identified genetic elements relative to speB start codon.   
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The AIs at high concentrations are recognized by their cognate sensory receptors and control the 
expression of genes involved in several bacterial traits, including virulence (120, 121, 123). Gram-
negative bacteria uses small chemical molecules as intercellular signals (121), whereas Gram-
positive bacteria uses either linear or modified oligopeptides to communicate with each other 
(120). The secreted extracellular peptides are sensed by either a membrane-bound sensor kinase 
of two-component signaling system or by intracellular transcription regulators (124). The 
intracellular quorum-sensing transcription regulators belong to the RRNPP family of regulators 
(4, 125-128). RRNPP family regulators comprises of the Rap phosphatases from Bacillus subtilis, 
Rgg from Streptococcus species, NprR from B. cereus group, PlcR from B. cereus group, and 
PrgX from Enterococcus faecalis (4, 71, 125, 126, 129). 
 
5. RopB  
RopB belongs to Rgg subfamily of RRNPP super family of transcription regulators. RopB 
influences the transcription of approximately 25% of the GAS genome during stationary phase of 
growth (71). Consistent with its role in SpeB regulation, genetic inactivation of ropB results in the 
attenuation of GAS virulence in animal models of GAS infection (4, 70, 130).  
RopB shares significant structural homology with the RRNPP family regulators (Fig. 7) 
(4, 71). All the characterized RRNPP family regulators use high bacterial population density-
specific linear oligopeptides as cognate signals and mediate target gene regulation (131, 132). The 
RRNPP regulators control several bacterial traits such as biofilm formation, virulence, sporulation, 
necrotrophic lifestyle, and antibiotic resistance (4, 133-135). Structurally, RRNPP family 
regulators are characterized by a two-domain architecture: an amino-terminal DNA binding 
domain, and a C-terminal peptide binding and oligomerization domain. The amino-terminal and 
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C-terminal domains are connected by a linker helix (Fig. 7) (125, 129, 132, 136, 137). With the 
exception of Rap phosphatases, all RRNPP regulators contain a helix-turn-helix (HTH) DNA 
binding motif in the amino-terminal domain that binds DNA. Contrary to this, the amino-terminal 
domain of Rap proteins contains a 3-helix bundle that directly interacts with a target transcription 
regulator and modulates gene expression by blocking the interactions between regulator-DNA (4, 
138-142). The C-terminal domain of the RRNPP family regulators are characterized by the 
Figure 7. Domain architecture of the RRNPP-family regulators. Overall architecture of the crystal 
structure of RapF bound to its cognate peptide signal ComA (pdb code: 3ULQ) (A), Rgg (pdb code: 4YV6) 
(B), RopB-CTD (pdb code: 5DL2) (C), NprR-CTD bound to its cognate peptide signal NprX (pdb code: 
4GPK) (D), PlcR bound to its cognate peptide signal PapR and DNA (pdb code: 3U3W) (E), PrgX bound 
to its cognate peptide signal cCF10 (pdb code: 2AXZ) (F) are shown. Residues colored in green represent 
the N-terminal domain, blue represent the C-terminal domain and the linker helix connecting both the 
domains are shown in orange. In panels B-F, ribbons colored in pink represent the second subunit of the 
dimer molecules. Black rectangle boxes show the concave peptide binding pockets. The cognate peptide 
signals of the respective regulator is shown as spheres located inside the box. Note: Surface residues on top 
of the peptide binding pocket are removed for panels A, D, E and F. Figure generated using Pymol (3). 
Adapted from (4).  
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presence of tandem repeats of tetratricopeptide repeat (TPR)-motifs. Each TPR motif is comprised 
of a pair of antiparallel helices, and TPR domains typically contain 5 TPR motifs (4). TPR domain 
of the RRNPP family regulators forms a right handed super helical structure which results in a 
convex exterior and a peptide or protein binding concave interior surface (Fig. 7) (4, 143). 
Typically, TPR motifs identified in eukaryotic and prokaryotic proteins are involved in protein-
protein or protein-peptide interactions (144, 145). Consistent with its structural homology, the C-
terminal domain of RopB also contain a TPR domain comprised of 5 TPR motifs (71). Given that 
RopB shares high degree of structural homology with RRNPP family regulators (4) and its role in 
population density-specific regulation of speB, it is likely that RopB uses GAS population density-
specific peptide signals to control speB expression. 
 
5.1 Peptide signals controlling the regulatory activity of RRNPP regulators 
The cognate mature peptide signals of the RRNPP regulators are linear, hydrophobic and 
short 5-8 amino acids long oligopeptides (4, 125). The peptide signals are synthesized as inactive 
pre-peptides in the bacterial cytosol (4, 146). The pre-peptides of cognate RRNPP regulators are 
encoded by small open reading frame (sORF) genes. The pre-peptides of Rap, NprR and PlcR are 
typically 40 – 50 amino acids in length, whereas the pre-peptides of Rgg regulators are 15 to 35 
amino acids long (125, 147). The peptide signals of the RRNPP family share several amino acid 
sequence traits: i) the peptides are made in their longer, pre-cursor form, ii) contain a recognizable 
amino-terminal secretion signal sequence required for the peptide secretion, iii) contain amino acid 
sequences that function as processing sites for intramembrane and/or secreted proteases, iv) during 
secretion, the pre-peptides undergo intramembrane and extracellular proteolytic processing that 
result in the release of mature active peptide signals (4, 118, 120, 146). The mature peptide signals 
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are imported back to the bacterial cytosol by the highly conserved oligopeptide transporter, Opp 
permeases (4, 125). The cytosolic cognate receptors senses the reinternalized peptides and the 
peptide-bound receptors mediate gene regulation (4, 125). Typically, the sORF encoding the 
cognate peptide signals of RRNPP family regulators are located in the immediate genetic vicinity 
of their respective regulators (Fig 8) (4, 125). However, our initial nucleotide sequence analysis of 
the genetic vicinity of ropB gene failed to identify a peptide signal-like sORF. As a result, RopB 
was considered as an orphan regulator.   
 
Figure 8. Genetic location of RRNPP family regulators and their cognate peptide signals. Blue arrows 
indicate the gene encoding the regulator and yellow arrows indicate the gene encoding the cognate peptide 
signal of the respective regulator. Transcription direction is indicated by the direction of the arrow.   
     
 
  AIM AND SCOPE OF THE STUDY 
33 | P a g e  
 
AIM AND SCOPE OF THE STUDY  
 Despite the significant advances in the understanding of structure and function of SpeB 
protease and its contribution to GAS pathogenesis, the precise molecular mechanisms governing 
speB gene regulation remain poorly understood (2). Given that the gene regulatory activity of 
RopB requires stationary growth phase-specific regulatory factor(s) and RopB shares structural 
homology with peptide-sensing RRNPP family of quorum-sensing regulators, we hypothesized 
that the factor responsible for stationary phase or high GAS population density-specific activation 
of speB expression is a peptide signal. Thus, the major goal of this study was to identify the peptide 
signal and characterize signaling mechanism during GAS growth in vitro and during infection.  
 To that end, the work presented in chapter 1 identifies and characterizes a novel peptide 
signal in the genetic vicinity of ropB that controls speB expression. However, the identified peptide 
signal is a leaderless peptide as it lacks several amino acid characteristics of characterized peptide 
signals. This lack of conformity hampered our initial efforts in the identification of peptide signal. 
Despite the lack of several traits of bacterial peptide signals, the cognate peptide signal for RopB 
is secreted, reimported into GAS cytosol, sensed by RopB, and control RopB-dependent speB gene 
expression. We further show the global impact of the peptide signal on the GAS transcriptome 
using RNA-sequencing studies. Finally, we show that the peptide signal pathway is active during 
infection and crucial for GAS virulence in multiple mouse models of infection.  
 In chapter 2, using ex vivo gene expression, mouse infection, and immunological studies , 
we show that the peptide signal pathway is active and control speB expression during GAS growth 
ex vivo in human saliva and blood. Importantly, we show that the peptide signaling pathway 
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contributes significantly to GAS survival ex vivo in human saliva and blood, and is critical for 
mouse oropharyngeal GAS colonization. 
  CHAPTER 1 





Leaderless secreted peptide signaling molecule alters global gene expression 
and increases virulence of a human bacterial pathogen 
Do H*, Makthal N*, VanderWal AR, Rettel M, Savitski MM, Peschek N, Papenfort 
K, Olsen RJ, Musser JM, Kumaraswami M. 
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Signaling by a Conserved Quorum Sensing Pathway Contributes to Growth Ex 
Vivo and Oropharyngeal Colonization of Human Pathogen Group A 
Streptococcus.  
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DISCUSSION  
The emergence of bacterial multidrug resistance against existing antibiotics and lack of 
new antibiotics in the pipeline pose a major threat to public health (5, 148-150). Thus, novel 
targeting strategies are urgently required to identify new antimicrobial targets to combat 
complicated infections caused by multidrug resistant bacteria. In this regard, the toxins produced 
by bacteria or signaling pathways controlling toxin production are ideal targets for antimicrobia l 
development as they contribute significantly to disease pathogenesis. An ideal antimicrobial target 
must be expressed during infection, participate in disease pathogenesis, and accessible in the host 
for therapeutic targeting (151-153). Given that cysteine protease SpeB is produced abundantly 
during human GAS infection (99, 100), and SpeB protease activity is a key contributor to GAS 
pathogenesis due to its role in various bacterial processes during infection (1, 2, 68, 72, 73, 96, 
154), it is a plausible candidate for antimicrobial targeting studies. Consistent with this, SpeB 
protease has been previously targeted for vaccine and antimicrobial development (104, 106). 
Although preclinical protection studies showed significant promise, the success has not translated 
to clinical trials (155). In this study, we have discovered that GAS produces a novel quorum-
sensing signal, a leaderless peptide SIP, which acts as an intercellular signal to control the 
expression of speB in concert with high bacterial population density. Contrary to all the 
characterized bacterial peptide signals, SIP amino acid sequence lacks several classical features 
that are required for peptide secretion and maturation. Nevertheless, SIP functions as an effective 
intercellular signal (chapter 1). In addition to SIP identification, we have deduced several 
mechanistic steps in the SIP signaling pathway that includes production of SIP in its mature form, 
and secretion and reinternalization of SIP to GAS cytosol by yet to be identified mechanisms. The 
reinternalized SIP is recognized by its cognate receptor, transcription regulator RopB, in the 
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cytosol. Binding of SIP induces allosteric changes in RopB that are crucial for activation of speB 
gene expression. Importantly, we showed that the SIP signaling pathway is active in vivo and 
contributes significantly to GAS virulence in mouse models of infection. We also showed that SIP 
signaling occurs during GAS growth ex vivo in human saliva and blood, and SIP-mediated speB 
expression is important for GAS survival in both saliva and blood. Given that SIP-dependent gene 
regulation is the primary signaling pathway that controls speB expression during infection, we 
propose that the molecular components of peptide signaling pathway may present alternate targets 
for therapeutic or prophylactic possibilities to treat GAS infections. However, further 
investigations are required to identify various components of this pathway for successful 
antimicrobial targeting.   
 
1. Mechanism of SIP export  
Without exception, the bacterial quorum sensing signals must be secreted to coordinate 
population-wide gene regulation (120, 126, 133-135). Gram-positive bacteria typically use 
oligopeptides as secreted signals, commonly referred to as peptide signals or auto-inducing 
peptides. The peptide signals are initially produced as inactive pre-peptides (125). Biogenesis of 
active (mature) peptide signals is a multi-step process involving secretion and proteolytic 
processing of the inactive pre-peptides. (4, 156). Generally, the peptide signals have three regions: 
the amino-terminus segment (n-region) rich in positively-charged amino acids, central core part 
(h-region) containing hydrophobic amino acids, and the C-terminus (c-region) fragment that has 
the protease recognition and cleavage region (107, 157). The basic n-region contains the 
characteristic secretion signal sequence that directs the translocation of the peptide signal to 
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bacterial membrane for secretion via the general secretory pathway (Sec) (4, 156, 158). The 
membrane-bound signal peptidase I then cleaves the secretion signal sequence as the peptide 
signals emerge from the Sec pathway (158). The c-region of the peptide signal typically contains 
one or more protease cleavage sites that are processed in the membrane by the intramembrane 
protease, enhanced expression of pheromone (Eep), and various secreted proteases (4, 125, 159). 
The extracellular peptide signals are subjected to additional processing by the secreted proteases 
before releasing the active (mature) peptide signal (127).   
 The biogenesis of mature SIP is unique compared to the hall marks of characterized 
bacterial peptide signals in other gram-positive bacteria. SIP is encoded in GAS genome as an 8-
amino acid peptide in its mature form. SIP lacks the amino acid sequence characteristics in the n-
region required for secretion (Fig. 3A of chapter 1). The lack of secretion signal sequence raises 
an important question – is SIP secreted? However, we demonstrated that the cell-free culture 
supernatant from peptide-producing WT GAS growth has regulatory activity, whereas the cell-
free culture supernatant obtained from the peptide non-producing sip* (start codon ATG mutated 
to stop codon TAG to disrupt the translation) mutant does not have the regulatory activity  (Fig. 
3D of chapter 1). These results showed that only the SIP-producing strains contain regulatory 
activity in the secreted component of GAS growth, thus establishing direct causation between the 
presence of intact sip gene in GAS genome and extracellular regulatory activity. Our efforts to 
provide direct evidence demonstrating the extracellular presence of SIP by mass-spectrometry are 
unsuccessful so far, likely due to the hydrophobic nature of SIP. In conclusion, despite the lack of 
a secretion signal sequence, SIP is secreted.  
SIP amino acid sequence also lacks protease cleavage sites in the c-region (Fig. 3A of 
chapter 1). SIP does not require proteolytic processing by Eep as the genetic inactivation of eep in 
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∆eep mutant did not affect speB expression (Fig. 3B and 3C of chapter 1), indicating that SIP is 
produced in its mature form.  
The dedicated PptAB exporter was previously shown to be required for the export of SHP, 
cognate peptide signals of Rgg regulators in Streptococcus (160, 161). However, our findings 
indicated that PptAB is not required for SIP signaling (unpublished data). Collectively, our 
analyses demonstrate that SIP is the founding member of a new class of leaderless peptide signals 
and is likely exported out of GAS cytosol by a yet-to-be identified novel secretion pathway.  
 
2. Import of extracellular SIP to the GAS cytoplasm   
The general paradigm of bacterial peptide signaling requires that the secreted mature 
peptide signals are recognized either extracellularly by the membrane-bound sensor kinase of two 
component systems or by the cytosolic transcription regulators (4, 125). The members of RRNPP 
family regulators are cytosolic peptide receptors that differentially regulate target gene expression 
upon their interactions with the cognate peptide signals (4, 125). Invariably, the import of cognate 
peptide signals of RRNPP family regulators into the cytosol is mediated by the membrane-bound 
peptide permeases, oligopeptide permeases (Opp) or dipeptide permeases (Dpp) (4, 125, 162-164). 
Both Opp and Dpp permeases are five subunit complexes that belong to the family of ATP-binding 
cassette (ABC) transporters (165-170). Typically, the opp and dpp genes are transcribed as a five-
gene operon and highly conserved across Gram-positive bacteria (165-170). Opp mediates the 
uptake of longer peptides (up to 35 residues), independent of their amino acid composition (165-
168), whereas Dpp permeases import dipeptides into the bacterial cytosol (171). As in other 
bacteria, two different five-gene operons, oppABCDF and dppABCDE, encoding Opp and Dpp 
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permeases, respectively, are present in the GAS genome. Previously, both Opp and Dpp permeases 
were implicated in the regulation of speB expression (164, 172). The role of peptide permeases in 
speB regulation combined with our discovery of SIP suggested that Opp or Dpp may influence 
speB expression due to their role in SIP reimport. However, our results revealed that genetic 
inactivation of opp (∆oppDF), or dpp (∆dppA) permeases in GAS M3 serotype did not affect speB 
expression (Fig. 3B of chapter 1). Given that the two permeases are highly conserved, we 
considered the possibility that the two importers may be functionally redundant, and inactivation 
of one importer may be compensated by the presence of second importer. To test this possibility , 
we generated a ΔoppDF/ΔdppA double mutant strain and measured speB transcript levels. 
Surprisingly, speB gene expression in the ΔoppDF/ΔdppA double mutant strain was comparable 
to that of WT GAS (Fig. 3B of chapter 1). Furthermore, addition of synthetic SIP to 
∆oppDF/∆dppA mutant restored WT-like speB expression in the ∆oppDF/∆dppA/∆sip strain (Fig. 
3B of chapter 1). Collectively, these observations suggest that Opp/Dpp permeases are not 
involved in SIP reimport. Importantly, the lack of a role for peptide permeases in SIP reimport 
raises a fundamental question: is SIP imported back to GAS cytoplasm? Our supplementation 
studies with fluorescein isothiocyanate (FITC)-labelled SIP unambiguously demonstrated that 
exogenously added SIP is internalized in GAS cytosol (Fig. 3F of chapter 1). Thus, it is likely that 
novel mechanisms are involved in SIP import. However, additional investigations will be required 
to fully elucidate the molecular details of SIP transport mechanisms.   
 
3. Binding of SIP to RopB and its implications in speB expression  
Despite the vast differences in the biogenesis, secretion and import mechanism between 
SIP and other RRNPP family signaling peptides, our results indicate that the underlying molecular 
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mechanism by which SIP influences speB regulation is consistent with the other members of the 
family. Typically, the mature peptide signals are 5 – 8 amino acid long, highly hydrophobic and 
modulate the expression of target genes by binding to their respective regulators with a high degree 
of specificity (4). Consistent with this, our protein-peptide binding studies (chapter 1) indicate that 
the intact SIP in its native order of amino acid sequence is engaged in high affinity and sequence-
specific interactions with RopB (dissociation constant Kd ~ 2.6 nM). Truncation of SIP by single 
amino acid disrupted RopB binding (Fig. 4A and 4B of chapter 1), indicating that full-length SIP 
is require for RopB interactions. The in vitro observations were recapitulated in vivo as single 
amino acid truncation of SIP failed to induce speB expression in sip* mutant strain (Fig. 2B of 
chapter 1). Thus we conclude that the binding of SIP to RopB regulator is a crucial step for the 
activation of speB expression. These findings were further corroborated by our structural studies 
in which we delineated the chemical basis for SIP recognition by RopB (173). We showed that 
SIP binds to the concave surface in the C-terminal domain of RopB. The SIP binding pocket is 
composed of hydrophobic and aromatic amino acids as well as asparagines that are characteristics 
of TPR domains (4). Importantly, the SIP-contacting RopB residues are crucial for the in vivo 
expression of SpeB and GAS virulence (173). Collectively, these results demonstrate that SIP 
recognition by RopB is crucial for the transcription regulation of speB. 
 The influence of environmental pH on the expression of speB is known for several decades 
(2). Caparon and group have reported that the speB expression was maximum when the in vitro 
culture medium was acidified to pH 6.0 and repressed at pH 7.5 (110). GAS auto-acidifies its 
growth conditions due to lactic acid production (from pH 7.5 during exponential growth phase to 
pH 6.0 during stationary phase) (2). Interestingly, the auto-acidification coincides with both high 
GAS population density and the onset of speB expression. These observations suggest the presence 
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of an interplay between environmental pH and SIP signaling. In accordance with this, our recent 
findings demonstrated that the binding affinity of SIP to RopB is sensitive to pH and high affinity 
interactions are favored under below neutral pH conditions (pH 6.0) (accepted manuscript). These 
results suggest that environmental pH controls SIP recognition by RopB. Compared to binding 
affinity (Kd value) in pH 6.0, the affinity was significantly reduced in buffer with pH 7.5 and pH 
9.0 by 23-fold and 177-fold, respectively (data not shown). Intriguingly, when environmental 
acidification occurs, GAS cytosol also acidified (pH 5.8), indicating that the cytosolic environment 
during high population density is the conducive for high affinity RopB-SIP interactions. We 
further demonstrated that a pH-sensing histidine switch is present in RopB that monitors 
environment pH and controls SIP binding to the pocket in RopB (173).  
In addition to pH, other GAS factors such as the two-component CovRS system, major 
transcription regulator Mga, transcription regulator CcpA also (Fig. 5 of Introduction) regulate 
SpeB production. However, how all these factors work, either individually or in tandem, to tightly 
modulate the production of SpeB is poorly understood (2). Given that SIP is the primary 
mechanism controlling speB expression and environmental pH is integrated into SIP pathway, it 
is possible that other GAS factors may exert their influence on speB expression by modulating SIP 
signaling pathway. Such discoveries would significantly advance our current understanding of the 
complex signaling peptide functions in GAS, and other pathogenic bacteria.     
 
4. Allosteric changes in RopB upon SIP binding 
Typically, the RRNPP family cognate peptides induce allosteric changes upon binding to 
their respective regulator, and these conformational changes in the regulators are crucial to the 
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target gene regulation (4). Among the RRNPP regulators, the binding of activation peptide cCF10 
disrupts PrgX tetramerization, which is crucial for the activation of gene expression. On the other 
hand, in Bacillus cereus, the binding of NrpX peptide to NrpR induces NrpR tetramerization which 
represents the transcriptionally active state of NprR (132, 174). Similarly, the binding of PapR to 
PlcR releases the otherwise masked N-terminal DNA binding domain of PlcR which leads to 
promoter binding and gene regulation (175). Our results indicate that SIP induces unique allosteric 
changes in RopB to activate speB expression. SIP facilitates high-affinity RopB-DNA interactions 
and subsequent polymerization of RopB on speB promoter to control gene expression. Although 
two different promoter sequences P1 and P2 have been implicated to be the involved in starting 
the transcription of speB (114), the role of P2 has been in question for several years now. Hence, 
we included the probe containing the sequence of P2 in our EMSA experiment to deduce its role 
in RopB regulatory activity. Our results show that both apo-RopB and RopB-SIP complex do not 
bind to the probe containing the promoter sequence of P2 (Fig. S6D of chapter 1) and these findings 
are consistent with the recent re-annotation of P2 promoter as a Rnase Y processing site of speB 
mRNA (116). Importantly, we show that SIP promotes RopB binding to two binding sites, site 1 
and site 2, in speB promoter. The two sites are located upstream of P1 and are separated by a 121-
bp-long spacer region (Fig. 4 and S6 of chapter 1). SIP also induces RopB oligomerization on the 
promoter sequences, however the DNA binding event precedes RopB oligomerization (Fig. 4I and 
S9 of chapter 1). Based on these findings, we propose that SIP promotes high affinity interactions 
between RopB and the two binding sites in P1. Using these interactions as nucleation event, RopB 
polymerizes between the spacer region of the two sites and the polymerization event of RopB 
results in the activation of speB transcription. Our future structural studies will be directed to 
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identify SIP-induced allosteric changes in RopB that contribute to RopB-DNA interactions and 
RopB oligomerization on DNA.  
 
5. Role of SIP in GAS pathogenesis 
The production/protease activity of SpeB has been extensively studied (2). The role of 
SpeB in GAS disease pathogenesis in animal models of infection and during natural human 
infections is well established (71, 72, 74, 75, 94, 95). Our in vitro analyses demonstrate that SIP 
signaling pathway is the primary regulatory mechanism controlling speB expression. However, the 
findings in the laboratory medium do not fully recapitulate the conditions encountered by GAS in 
the complex host environment (2). This led us to ask a three-part question (i) whether SIP is 
produced during GAS infection, ii) whether SIP signaling pathway is active during GAS infection 
in the host, and iii) whether SIP signaling pathway contributes to GAS pathogenesis. Our findings 
in chapter 2 show that the serum samples obtained from 5 convalescing patients with prior invasive 
GAS infections and 5 pediatric patients with GAS pharyngitis had anti-SIP antibodies, suggesting 
that SIP is produced by GAS in the host during infection (Table 1 of chapter 2). To answer the 
second and third part of the question, we compared the in vivo speB expression levels in mice 
infected subcutaneously with one of the following strains: WT, sip* mutant, and sip* mutant trans-
complemented with sip.  We have used WT GAS strain grown to late-exponential phase in the 
laboratory medium as the reference. We observed a ~ 3000-fold increase in speB transcript levels 
in WT GAS compared to the reference.  However, the sip* mutant strain had speB transcript levels 
comparable to that of reference (Fig. 6A of chapter 1), indicating that SIP signaling pathway is 
active and controls speB expression in vivo during infection. Overall, these results (Fig. 1D of 
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chapter 1) demonstrate that SIP is produced during infection and intercellular SIP signaling 
pathway activates GAS virulence gene regulation in the complex host environment.  
GAS is a versatile pathogen that infects several host niches. Given the variations in the 
complex host milieu at different host anatomical sites, it is remarkable that GAS possess 
mechanisms to colonize and establish infections in diverse host environments (12, 19). In this 
regard, we raised the question whether SIP signaling pathway contributes to GAS pathogenesis at 
different host anatomical sites (Fig. 5 of chapter 1).   
The host oropharynx is the most common site for GAS colonization and pharyngitis is the 
common form of GAS disease manifestation (13, 176). GAS employs unique transcriptional 
program to survive in human saliva and colonize oropharynx. Among the GAS genes upregulated 
during growth in saliva, SpeB is critical for optimum GAS growth ex vivo in human saliva (77, 
177). This is not surprising considering the fact that saliva is the first line of host defense and 
contains antimicrobial peptides such as LL37 to control pathogen growth (76, 178). Using the ex 
vivo growth conditions, we demonstrated that addition of synthetic SIP activates speB expression 
in the sip* mutant during growth ex vivo in human saliva and blood. These observations suggest 
that SIP signaling occurs during growth in human body fluids and SIP signaling pathway is the 
primary regulatory mechanism that controls speB expression. Furthermore, when comparing the 
growth kinetics of WT, sip*, and trans-complemented strains for survival in human saliva and 
oropharyngeal colonization, the SIP non-producing strains were significantly impaired in growth 
ex vivo in human saliva and oropharyngeal colonization compared to SIP-producing strains (Fig. 
4A and Fig. 5B of chapter 2). Given that the oropharynx is the primary route of GAS entry, our 
discovery that the SIP-mediated speB regulation is critical for GAS colonization in the host is of 
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particular importance as this can lead to translational strategies targeting SIP signaling pathway to 
control GAS survival in the oropharynx (Fig. 4B of chapter 2).  
 
6. General model of quorum sensing mediated regulation of SpeB 
 The ability of bacterial pathogens to sense environmental cues and mediate spatiotemporal 
regulation of virulence factors is crucial for successful survival in the host (107, 120, 121, 179, 
180). In this regard, GAS employs multilayered regulatory mechanisms to coordinate speB 
expression in concert with high bacterial population density. We have previously demonstrated 
that the transcription of speB is negatively influenced by the N-terminal secretion signal peptide 
of virulence factor related (Vfr) protein during low bacterial population density (107). Although 
the exact identity of the peptide sequence was not determined, our results indicated that the mature 
peptide resides in the N-terminal 40 amino acids of Vfr and modulates speB expression by binding 
to RopB (107). Based on these observations, we propose the following model (Fig. 6E of chapter 
1) for population density-dependent regulation of speB expression. The mature Vfr peptide 
produced during low GAS population density binds to RopB and negatively influences speB 
expression. Conversely, during high GAS population density, the expression of vfr is 
downregulated and sip expression is induced. Once SIP reaches the threshold concentration, it 
binds to RopB and induces RopB-dependent activation of speB expression (Fig. 6E of chapter 1). 
SIP production also activates the positive feedback loop causing robust induction of sip and speB 
expression. Similar mode of gene regulation was observed in PrgX from Enterococcus faecalis. 
As in RopB, PrgX has two cognate peptides, an inhibitory peptide, iCF10 and an activation 
peptide, cCF10. Both peptides compete to bind to the PrgX protein and modulate the gene 
regulation activity of PrgX (181).  
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7. Perspectives and future directions  
 The Rgg/Rap/NprR/PlcR/PrgX proteins constitute the founding members of RRNPP 
family of regulators in gram-positive bacteria. However, bioinformatics analyses of bacterial 
genomes suggest that a large number of RRNPP homologs exist in different bacteria (125, 129). 
The cognate signaling peptides of the prototypical RRNPP family regulators have been identified. 
However, the cognate signaling peptides for most of these homologs are yet to be identified. RopB 
forms a subfamily of Rgg regulators. A major challenge in identifying the cognate peptide signals 
for RopB-like regulators is that the sORFs encoding non-canonical SIP-like bacterial peptide 
signals that are produced in its mature form. Thus, identification of such bacterial peptide signals 
using the criteria for classical bacterial peptide signals can be unsuccessful (125, 182). In this 
regard, our discovery of SIP provides a roadmap for the identification of SIP-like leaderless 
peptide signals and accelerate the discovery of the similar leaderless peptide signals in other 
bacteria. Furthermore, identification of SIP also underscores the complexities associated with 
bacterial intercellular communication pathways and expands the repertoire of bacterial languages.  
 In pathogenic bacteria, quorum sensing pathways play a significant role in the regulation 
of crucial traits such as virulence, sporulation, biofilm formation, and antibiotic resistance (71, 
133-135, 183). Although we have elucidated the identity of the peptide signal controlling virulence 
gene regulation in GAS, several steps of this pathway remain poorly understood. Specifically, the 
molecular mechanisms by which SIP is secreted and brought back to the GAS cytosol are 
unknown. Thus, investigations into other aspects of SIP signaling will establish the basic principles 
of leaderless peptide signaling and will likely identify previously unknown therapeutic targets and 
strategies.      
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